🔎 Trials Near Me

Home › Burkitt-lymfoom › South Dakota

Burkitt-lymfoom klinische studies in South Dakota

5 studies voor Burkitt-lymfoom zoeken deelnemers op locaties in South Dakota.

Steden in South Dakota

Officiële studietekst (Engels)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
RekruterenFase 2
366 Days – 46 Years · Alle geslachten · Bijgewerkt 2 okt. 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
RekruterenFase 2
365 Days · Alle geslachten · Bijgewerkt 25 sep. 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls
RekruterenFase 1/2
6 Months – 25 Years · Alle geslachten · Bijgewerkt 17 sep. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
RekruterenFase 2
Leeftijden 1 tot 30 · Alle geslachten · Bijgewerkt 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
RekruterenFase 3
365 Days – 25 Years · Alle geslachten · Bijgewerkt 25 aug. 2026 · NCT03959085

Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.